Madrigal Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
MDGL Nasdaq 2834 www.madrigalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Aug 6th, 2026 2:05 pm
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Aug 6th, 2026 6:00 am
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls - Aug 4th, 2026 7:37 am
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More - Aug 4th, 2026 6:11 am
Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value? - Jul 31st, 2026 12:09 pm
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth - Jul 31st, 2026 9:34 am
Madrigal Pharmaceuticals Q2 Earnings Call Highlights - Jul 30th, 2026 12:04 pm
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates - Jul 30th, 2026 6:35 am
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates - Jul 30th, 2026 5:00 am
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates - Jul 29th, 2026 4:25 pm
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners - Jul 27th, 2026 8:38 am
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 - Jul 16th, 2026 6:00 am
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Jul 13th, 2026 5:47 pm
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio - Jul 13th, 2026 6:00 am
3 Under-the-Radar Stocks to Buy and Hold - Jul 10th, 2026 12:50 pm
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Jul 8th, 2026 1:20 pm
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Jul 1st, 2026 7:29 pm
3 late-stage MASH drugs that could rival Rezdiffra - Jun 29th, 2026 3:00 am
3 Under-the-Radar Stocks to Buy and Hold for a Decade - Jun 16th, 2026 1:50 am
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Jun 9th, 2026 12:14 am